Accessibility Menu
 
Arrow-Thin-Down
S&P 500
7,209.01
+1.0%
+73.06
Arrow-Thin-Down
DJI
49,652.14
+1.6%
+790.33
Arrow-Thin-Down
NASDAQ
24,892.31
+0.9%
+219.07
Arrow-Thin-Down
Bitcoin
$77,253.00
+1.5%
+$1,150.96
Arrow-Thin-Down
AAPL
$270.97
+0.3%
+$0.80
Arrow-Thin-Down
AMZN
$265.06
+0.8%
+$2.02
Arrow-Thin-Down
GOOG
$381.94
+10.0%
+$34.63
Arrow-Thin-Down
META
$611.91
-8.6%
-$57.21
Arrow-Thin-Down
MSFT
$407.91
-3.9%
-$16.55
Arrow-Thin-Down
NVDA
$199.98
-4.4%
-$9.27
Arrow-Thin-Down
TSLA
$381.92
+2.4%
+$9.12
Most Active StocksDaily Stock GainersDaily Stock Losers

This Hims & Hers Move Could Destroy Competitors

The Wegovy pill could change Hims & Hers' growth in 2026.

By Travis Hoium – Mar 21, 2026 at 6:00AM EST

Key Points

  • The recent deal between Novo Nordisk and Hims & Hers is already resulting in new product announcements for Hims & Hers.
  • The fastest GLP-1 launch in history could be boosted by a wider distribution funnel.
  • This could bring growth back to Hims & Hers in 2026.

Hims & Hers (HIMS +3.19%) has had a rough go of it in 2026, but a recent deal with Novo Nordisk (NVO +4.79%) may bring the company's operations back to life. The Wegovy pill is one of the products coming to Hims & Hers, and we now know details of what that launch will look like, and it could make this a high-growth stock by the end of 2026. In this video, I explain why this launch is so exciting.

*Stock prices used were end-of-day prices of March 18, 2026. The video was published on March 20, 2026.

Read Next

About the Author

Travis Hoium
Travis Hoium is a contributing Motley Fool stock market analyst covering solar energy, technology, and growth stocks. Before The Motley Fool, Travis was a mechanical engineer at 3M and founded a virtual reality company. He holds a bachelor’s degree in mechanical engineering and a master’s degree in business administration from the University of Minnesota.
TMFFlushDraw
X@travishoium

Travis Hoium has positions in Hims & Hers Health. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Travis Hoium is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.

Stocks Mentioned

Novo Nordisk Stock Quote
Novo Nordisk
NYSE: NVO
$42.22
(+4.79%)+$1.93
Eli Lilly Stock Quote
Eli Lilly
NYSE: LLY
$934.60
(+9.80%)+$83.39
Hims & Hers Health Stock Quote
Hims & Hers Health
NYSE: HIMS
$27.17
(+3.19%)+$0.84

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services